About Sinntaxis
Sinntaxis is a company based in Lund (Sweden) founded in 2017. Sinntaxis offers products and services including mGluR5 Inhibitors. Sinntaxis operates in a competitive market with competitors including Acticor Biotech, Remedy Pharmaceuticals, Basking Biosciences, Alveron Pharma and Remedium Bio, among others.
- Headquarter Lund, Sweden
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website sinntaxis.com
- Legal Name Sinntaxis Ab
- Latest Funding Round$104.75K (USD), Grant
Nov 2020
- InvestorsEuropean Union
& 2 more
Products & Services of Sinntaxis
Sinntaxis offers a comprehensive portfolio of products and services, including mGluR5 Inhibitors.
Drugs that enhance recovery of brain functions after stroke.
Funding Insights of Sinntaxis
- Total Rounds 3
- Last Round Grant — $104,752
- First Round $57,304
(Jan 2019)
- Investors Count 3
All 3 funding rounds of Sinntaxis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2020 | $104,752 | Grant | – | – | |
| Jun 2019 | $56,834 | Grant | – | – | |
| Jan 2019 | $57,304 | Grant | – | – |
3 investors in total: 3 institutional.
Investors in Sinntaxis
Sinntaxis has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union, Vinnova and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital funding is provided to Swedish companies across sectors. | 2001 | vinnova.se | Stockholm, Sweden | |
Government agency and accelerator focusing on innovative startups and SMEs | – | eicfund.eu | Brussels, Belgium | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Sinntaxis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Sinntaxis
1 people are tracked at Sinntaxis (1 in leadership).
| Name | Role | Group |
|---|---|---|
Tomas Eriksson | CEO | Leadership |
Complete people profiles for Sinntaxis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Sinntaxis
3 dated milestones of Sinntaxis across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Sinntaxis is founded.
- Funding First funding round of $57K.
- Funding Latest funding round, Grant, of $105K.
Competitors of Sinntaxis
Sinntaxis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Acticor Biotech, Remedy Pharmaceuticals, Basking Biosciences, Alveron Pharma and Remedium Bio, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| acticor-biotech.com | 2013 | Paris, France | $31.36M | – | Immunotherapeutics are developed for ischemic stroke treatment using monoclonal antibodies. | |
| remedypharmaceuticals.com | 2004 | New York, United States | $22.76M | 6 | Intravenous formulation for acute central nervous system conditions such as stroke (ischemic and hemorrhagic), traumatic brain injury. | |
| baskingbiosciences.com | 2019 | Columbus, United States | $89.8M | 3 | Therapeutics for ischemic stroke treatment are developed. | |
| alveron.com | 2019 | Nijmegen, Netherlands | $11.79M | – | Drugs for haemorrhagic stroke and intracranial haemorrhage are developed. | |
| remedium-bio.com | 2020 | Needham, United States | $3.5M | – | Gene therapies for immune and age-related conditions are developed. | |
| zzbiotech.com | 2006 | Houston, United States | – | – | Genetically engineered proteins for stroke and brain disorders are developed. | |
| aurumbiosciences.com | 2015 | Glasgow, United Kingdom | $6.3M | 6 | Novel oxygen carriers and MRI software for stroke are developed. | |
| magpiepharma.com | 2016 | Guangzhou, China | $29.14M | – | Developer of small molecules for the treatment of stroke and other heart diseases | |
| snebio.com | 2019 | Seoul, South Korea | $7.34M | – | Cell therapies for neurological disorders are developed using extracellular vesicles. |
Detailed competitors of Sinntaxis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sinntaxis
Complete news archive for Sinntaxis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Sinntaxis
10 companies that operate in the same segment as Sinntaxis (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Sinntaxis
Sinntaxis was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Sinntaxis is headquartered in Lund, Sweden.
Tomas Eriksson is the current CEO of Sinntaxis.
Sinntaxis was founded in 2017 in Lund, Sweden, within the biotechnology sector. Small molecule-based therapeutics are being developed for stroke recovery, specifically negative allosteric modulators of the metabotropic glutamate receptor 5. These modulators are designed to remodel brain connectivity via synaptic remodeling processes. Operations are based in Sweden, with a focus on advancing treatments for neurological recovery.
Sinntaxis's top competitors include Acticor Biotech, Remedy Pharmaceuticals and Basking Biosciences.
Sinntaxis offers mGluR5 Inhibitors.
Sinntaxis has 3 investors. Key investors include European Union, Vinnova, and EIC Fund.
Sinntaxis operates through Sinntaxis Ab.